Brain metastases
NVCRNovoCure LimitedCatalyst overview
Research summary
This catalyst tracks a PDUFA approval decision for Stereotactic radiosurgery (SRS) w/ NovoTTF-200M in Brain metastases. The expected timing is based on the latest available company guidance and may change.
07/23/26:- FDA decision on METIS brain metastases PMA reiterated for Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.